We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
44 hedge funds and large institutions have $20.7M invested in CASI Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
76% more capital invested
Capital invested by funds: $11.8M → $20.7M (+$8.95M)
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
16% more funds holding
Funds holding: 38 → 44 (+6)
0.16% more ownership
Funds ownership: 0.55% → 0.71% (+0.16%)
Holders
44
Holders Change
+6
Holders Change %
+15.79%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Millennium Management
New York
|
+$1.45M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
| 3 |
WSC
Wellington Shields & Co
New York
|
+$672K |
| 4 |
Goldman Sachs
New York
|
+$594K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$406K |
| 2 |
PA
Perceptive Advisors
New York
|
-$149K |
| 3 |
Barclays
London,
United Kingdom
|
-$76.6K |
| 4 |
RE
RBC Europe
London,
United Kingdom
|
-$65K |
| 5 |
AGM
Alpine Global Management
New York
|
-$58.9K |
